Purpose of review The most substantial advancement in the treatment of indolent B-cell non-Hodgkin lymphoma (NHL), since the advent of combination chemotherapy, has been the introduction of the monoclonal anti-CD20 antibody rituximab. However, the optimal schedule, timing, and duration of rituximab therapy remain controversial. Recent findings Since its initially reported single-agent activity in 1997, the role of rituximab has greatly expanded and it is now ubiquitously integrated in all treatment phases of indolent NHL. Yet, several questions remain to be addressed: should asymptomatic patients be treated at diagnosis with single-agent rituximab or still kept in watchful waiting, what are the optimal first-line treatments to combine with rituximab, what is the role of maintenance therapy, and is there a benefit in incorporating rituximab in autologous and allogeneic stem cell transplantation schemes for these diseases? Recent and ongoing clinical trials tackling these relevant issues will be presented and critically discussed in this article. Summary Excellent outcomes are reported with rituximab therapy in indolent NHL, both early and late in the disease course. Continued study of this most valuable therapeutic agent is warranted to set the optimal treatment approach leading to cure the majority of patients.
Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation / N. Cieri, O. Di Bartolo, P. Corradini. - In: CURRENT OPINION IN HEMATOLOGY. - ISSN 1065-6251. - 22:6(2015), pp. 469-475.
|Titolo:||Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation|
CIERI, NICOLETTA (Primo)
CORRADINI, PAOLO (Ultimo)
|Parole Chiave:||Follicular lymphoma; Hematopoietic stem cell transplantation; Immunotherapy; Indolent non-hodgkin lymphoma; Hematology|
|Settore Scientifico Disciplinare:||Settore MED/15 - Malattie del Sangue|
|Data di pubblicazione:||2015|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1097/MOH.0000000000000180|
|Appare nelle tipologie:||01 - Articolo su periodico|